ANL

Accretion Nutraveda Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal policy. The trading window will reopen 48 hours after the declaration of the unaudited financial results for the half-year ended September 30, 2026, to the BSE Limited. This measure is standard practice to prevent potential insider trading during periods when material non-public information may be available.

Accretion Nutraveda Ltd's Board of Directors met on September 1, 2026, approving several key proposals. These include alterations to the company's Memorandum of Association (MOA) to expand its business objectives, an increase in borrowing limits under Section 180(1)(c) of the Companies Act, 2013, and an enhancement of limits for creating charges on company property under Section 180(1)(a). The board also approved advancing loans and providing guarantees/security under Sections 185 and 186 of the Companies Act, 2013. These approvals are subject to shareholder and regulatory clearances.

Accretion Nutraveda Ltd announced that its Board of Directors, in a meeting held on September 1, 2026, approved several key proposals. These include the alteration of the Object Clause in the Memorandum of Association (MOA) to expand business activities, particularly in nutraceuticals and pharmaceuticals. The board also approved increasing borrowing limits under Section 180(1)(c) of the Companies Act, 2013, and enhancing limits for creating charges on company property under Section 180(1)(a). Furthermore, proposals for advancing loans, providing guarantees, and making investments exceeding prescribed limits under Sections 185 and 186 were approved. These approvals are subject to shareholder and regulatory clearances.

Accretion Nutraveda Ltd announced that its Board of Directors, in a meeting held on September 1, 2026, approved several key proposals. These include the alteration of the Memorandum of Association (MOA) to expand its object clause, particularly in the nutraceuticals and pharmaceuticals sectors. The board also approved increasing borrowing limits under Section 180(1)(c) of the Companies Act, 2013, and enhancing limits for creating charges on company property under Section 180(1)(a). Furthermore, proposals for advancing loans, providing guarantees, and making investments exceeding prescribed limits under Sections 185 and 186 were approved. These approvals are subject to shareholder and regulatory clearances.

Accretion Nutraveda Ltd has informed shareholders about the availability of the Annual Report for FY 2025-26 and the Notice for the 5th Annual General Meeting (AGM). For shareholders whose email addresses are not registered, a letter containing a web link and path to access these documents has been dispatched. The AGM is scheduled for August 27, 2026, to be held via Video Conference/Other Audio-Visual Means. Shareholders are encouraged to update their email addresses for easier access to company information.

Accretion Nutraveda Limited has been honored with the 'Global Export Excellence Award in Ayurvedic & Nutraceutical Manufacturing' at the 'Leaders of Navbharat Award & Conclave' organized by the Times Now Group. This recognition highlights the company's achievements in the export of Ayurvedic and nutraceutical products. The award underscores Accretion Nutraveda's commitment to quality and its growing presence in international markets within the health and wellness sector.

Accretion Nutraveda Limited (BSE SME: ANL) reported strong financial results for H2 FY26 and FY26. H2 FY26 revenue increased by 80.09% YoY to ₹19.54 crore, and EBITDA grew by 42.64% YoY to ₹3.68 crore. FY26 revenue rose by 110.00% YoY to ₹33.60 crore, with EBITDA up 87.94% YoY to ₹7.01 crore. The company's Managing Director, Mr. Mayur Popatlal Sojitra, highlighted the successful IPO and listing on the BSE SME Platform, which will support future expansion plans.

Accretion Nutraveda Ltd has appointed M/s. U M T & Co., Chartered Accountants, as the Internal Auditor for the Financial Year 2026-27. The appointment was approved during the Board Meeting held on May 8, 2026. Additionally, M/s. Sakhiya & Co., Company Secretaries, were re-appointed as Secretarial Auditors for the same financial year. The board also approved the audited financial results for the year ended March 31, 2026, with an unmodified opinion from the Statutory Auditors, M/s. V S S B & Associates.

Accretion Nutraveda Ltd has re-appointed M/s. Sakhiya & Co. as Secretarial Auditors for FY 2026-27 and appointed M/s. U M T & Co. as Internal Auditor for FY 2026-27, as decided in the Board Meeting held on May 8th, 2026. The board also approved the audited financial results for the year ended March 31st, 2026, with an unmodified opinion from Statutory Auditors M/s. V S S B & Associates.

Accretion Nutraveda Ltd has appointed Ms. Grishma A Shewale as an Additional Non-Executive Independent Director. The Board also approved the audited financial results for the year ended March 31, 2026, with an unmodified opinion from auditors M/s. V S S B & Associates. M/s. Sakhiya & Co. was re-appointed as Secretarial Auditors for FY 2026-27, and M/s. U M T & Co. was appointed as Internal Auditor for FY 2026-27.